Relamorelin: Phase II data

A double-blind, U.S. Phase II trial in 22 females with anorexia nervosa showed that once-daily 100 ug subcutaneous relamorelin led

Read the full 205 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE